Rigel Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 0/6
Rigel Pharmaceuticals has a total shareholder equity of $-14.6M and total debt of $99.7M, which brings its debt-to-equity ratio to -681.5%. Its total assets and total liabilities are $139.4M and $154.1M respectively. Rigel Pharmaceuticals's EBIT is $9.4M making its interest coverage ratio 1.7. It has cash and short-term investments of $61.1M.
Key information
-681.5%
Debt to equity ratio
US$99.74m
Debt
| Interest coverage ratio | 1.7x |
| Cash | US$61.11m |
| Equity | -US$14.64m |
| Total liabilities | US$154.06m |
| Total assets | US$139.42m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RI2 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: RI2 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: RI2 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: RI2's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: RI2's debt is not well covered by operating cash flow (10.8%).
Interest Coverage: RI2's interest payments on its debt are not well covered by EBIT (1.7x coverage).